Echocardiographic Characterization of Cardiac Amyloidosis

Fondazione Policlinico Universitario Agostino Gemelli IRCCS255 enrolled

Overview

This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Rome, Italy) will be enrolled. The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype. Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

Study Type

OBSERVATIONAL

Enrollment

255

Conditions

Cardiac Amyloidosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit. Exclusion Criteria: * missing data * decline to the study participation

Locations (1)

Outcomes

Primary Outcomes

changes in echocardiographic parameters (in patients receiving or not specific treatment)

variation in global longitudinal strain, diastolic parameters and degree of ventricular hypertrophy

Time frame: 6 months

cardiovascular outcomes

composite endpoint of death and heart failure hospitalization

Time frame: 24 months

Secondary Outcomes

major cardiac arrhythmias

bradyarrhythmia, new-onset atrial fibrillation, ventricular tachycardia